SPRY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ARS Pharmaceuticals has the Momentum Rank of 0.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of ARS Pharmaceuticals's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander A Fitzpatrick | officer: Chief Legal Officer | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Laura Shawver | director, officer: Chief Executive Officer | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Capital Gp Vi Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Capital Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Brian Dorsey | officer: Chief Operating Officer | C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130 |
Kathleen D. Scott | officer: Chief Financial Officer | C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127 |
Pratik Shah | director, 10 percent owner | 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037 |
Jonathan S Leff | director | C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Private Design Fund Iv, L.p. | director, 10 percent owner, other: * Director by deputization | 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Mgmt Iv, L.p. | director, 10 percent owner, other: * Director by deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Ra Capital Nexus Fund Ii, L.p. | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Brent L Saunders | director | 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033 |
From GuruFocus
By ACCESSWIRE • 10-09-2023
By Marketwired • 10-06-2023
By Marketwired • 09-28-2023
By Marketwired • 10-03-2023
By Marketwired • 10-23-2023
By Marketwired • 10-09-2023
By GuruFocus Research • 10-03-2023
By Marketwired • 10-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.